Korea Biomedical Review | 2024-06-27
Mediwhale, a medical AI diagnostic solution provider, said Thursday that it has been selected as a “JLABS” company, benefitting from a global accelerator platform operated by Johnson & Johnson Innovation, a multinational pharmaceutical giant.
Mediwhale’s “Dr. Eye (Reti-CVD)” (Courtesy of Mediwhale)
JLABS picks companies through a rigorous, months-long evaluation process. Selected companies will have access to a broad range of expertise, research advice, and global networks across the pharmaceutical and medical technology sectors from JLABS offices worldwide.
JLABS is a specialized accelerator organization under Johnson & Johnson with locations in 11 regions (seven in North America, one in Europe, and three in Asia). This year, it established JLABS Korea, which was selected to operate the Ministry of Health and Welfare’s global accelerator platform to help Korean biopharmaceutical and medical device companies accelerate their access to global markets.